Cabaletta Bio

Cabaletta Bio

Cabaletta Bio

Cabaletta Bio has adapted clinicallyvalidated and FDAapproved CAR T cell technology to target B cellmediated autoimmune diseases with its CAAR T cell technology.
Raised
$50M
Follow us
Alexa global traffic share